Published in Cancer Weekly, May 20th, 2008
"They were classified into three groups: those aged 40 years or less (''young,'' 12.7%); those aged 41-65 years (''middle-aged,'' 66.7%); and those aged more than 65 years (''elderly,'' 20.6%). Clinicopathologic characteristics and overall survival rates were analyzed. Young patients were predominately female and had tumors that were histologically undifferentiated. However, in regard to T4...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.